相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment
Nadia Bolandi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials
F. Pietrantonio et al.
ESMO OPEN (2021)
Microsatellite instability in Gastric Cancer: Between lights and shadows
Elisabetta Puliga et al.
CANCER TREATMENT REVIEWS (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study
Tong Xie et al.
JOURNAL OF IMMUNOTHERAPY (2020)
The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery
Wen-Liang Fang et al.
CANCERS (2020)
The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer
Lei Cai et al.
FRONTIERS IN ONCOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives
Keran Sun et al.
FRONTIERS IN ONCOLOGY (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma
Atsuhito Nakayama et al.
PLOS ONE (2019)
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Jeffrey M. Conroy et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Pengfei Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N. Boku et al.
ANNALS OF ONCOLOGY (2019)
Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines
Kyle Ellrott et al.
CELL SYSTEMS (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas
Gilbert Bigras et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer
K. Polom et al.
BRITISH JOURNAL OF SURGERY (2018)
Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications
Ruri Saito et al.
MODERN PATHOLOGY (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Clinical and pathological characterization of Epstein-Barr virus-associated gastric carcinomas in Portugal
Joana Ribeiro et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Prevalence and characteristics of Epstein-Barr virus-associated gastric carcinomas in Portugal
Celia Nogueira et al.
INFECTIOUS AGENTS AND CANCER (2017)
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability
Changqing Ma et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
Update on Epstein-Barr virus and gastric cancer
Aya Shinozaki-Ushiku et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis
M. Constanza Camargo et al.
GUT (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Meta-analysis Shows That Prevalence of Epstein-Barr Virus-Positive Gastric Cancer Differs Based on Sex and Anatomic Location
Gwen Murphy et al.
GASTROENTEROLOGY (2009)
Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma
HS Lee et al.
CLINICAL CANCER RESEARCH (2004)
Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications
JL Hsu et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2000)
分享论文
